Japan Begins Using PD-L1 Expression Biomarker for Immune Checkpoint Inhibitors, but Challenges Linger

Japan has started using PD-L1 expression testing to predict the efficacy of immune checkpoint inhibitors upon the debut of MSD’s anti-PD-1 antibody Keytruda (pembrolizumab), with its use also pushed for the drug’s first-in-class rival Opdivo (nivolumab). While such test could...read more